Fig. 2.
High expression of SERINC2 predicts poor prognosis in LGG but has no effect on OS of GBM patients. a–c High expression of SERINC2 showed shorter 5-year (a), 10-year (b), and 15-year (c) OS in the TCGA-LGG dataset, but no significance was found in TCGA-GBM (d). e–h The same results were found in the GSE16011 dataset; LGG patients with high SERINC2 expression had shorter 5-year (e), 10-year (f), and 15-year (g) OS, and GBM patients showed no significance (h)